AI biotech Isomorphic Labs is not slowing down, exec says
“All of our AI models are locked down and locked down in-house,” Chris Butler, who runs drug discovery at the Google-backed drug company, said at Semafor’s Future of Health Forum.
Isomorphic Labs, a Google-backed biotech firm founded by DeepMind's Demis Hassabis, is not slowing down despite calls for AI companies to pace forward, according to Chris Butler, who leads drug discovery at the company. At the Semafor Future of Health Forum, Butler emphasized that Isomorphic's internal AI models remain untouched, allowing the firm to continue accelerating the drug discovery process.
The company, which was spun off from DeepMind in 2021, recently raised $2.1 billion in funding to bolster its drug design capabilities, with a focus on oncology and immunology. Butler reported that Isomorphic is progressing smoothly through preclinical development and has established collaborations with Novartis, Eli Lilly, and Johnson & Johnson.
The executive also acknowledged the evolving regulatory landscape surrounding AI in drug development and highlighted the importance of working closely with regulators to ensure successful progression of their molecules.
Written by urgent.news from Semafor's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
